With few exceptions, the most commonly recommended triple Helicobacter pylori regimen
(proton pump inhibitor (PPI), amoxicillin and clarithromycin) now provides unacceptably low …

AIM: To investigate the epidemiology of Helicobacter pylori (H. pylori) infection among the
healthy asymptomatic population in Iran and countries of the Eastern Mediterranean Region …

OBJECTIVES: Resistance to standardHelicobacter pylori (HP) treatment regimens has led to
unsatisfactory cure rates in HP-infected patients. This study was designed to evaluate a …

Objectives Despite excessive resistance of Helicobacter pylori to clarithromycin among the
Iranian population, clarithromycin-based therapy is still prescribed in Iran. Recent studies …

Helicobacter pylori (H. pylori) infection is one of the most common bacterial infections,
affecting almost half of the world's population. It is associated with peptic ulcer disease …

Background Treatment success of H. pylori eradication therapy has declined worldwide
largely because of increased antimicrobial resistance. New therapeutic approaches are …

Background and aims The decreasing Helicobacter pylori eradication rate and the
increasing antibiotic resistance trend are of great concern. Therefore, new and effective …

AIM: To evaluate the efficacy of furazolidone-based triple and quadruple therapy in
eradicating Helicobacter pylori (H. pylori) in a multi-center randomized controlled trial …

Results: Following furazolidone-based first-line therapy, H. pylori eradication rates were
75.7% and 79.6% at ITT and PP analysis, respectively (P< 0.001). The overall incidence of …

Background Bismuth‐containing quadruple therapy (BQT) is a recommended alternative first‐
line therapy for Helicobacter pylori (H. pylori) infection. We aim to evaluate the efficacy and …